Improved viral suppression after treatment optimization in HIV-infected patients with persistent low-level Viremia

Journal of Acquired Immune Deficiency Syndromes

Volumn 58, Issue 5, 2011, Pages 446-449

  McConnell, Michael J ^a   Mier Mota, Julian ^a   Flor Parra, Fernando ^a   Martinez Fernandez, Francisco J ^a   Lopez Cortes, Luis F ^a   Viciana, Pompeyo ^a   Fernandez Cuenca, Felipe ^b   Perez Romero, Pilar ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

Author keywords

genotyping; HIV; persistent low level viremia; treatment optimization

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; GENE MUTATION; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PATIENT COMPLIANCE; PERSISTENT LOW LEVEL VIREMIA; PRIORITY JOURNAL; TREATMENT RESPONSE; VIREMIA; VIRUS INHIBITION; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; GENE EXPRESSION REGULATION, VIRAL; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MALE; MIDDLE AGED; VIRAL LOAD; VIREMIA;

EID: 81755174325     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3182364513     Document Type: Article

References (14)

1. Pham T, Alrabaa S, Somboonwit C, et al. The HIV virologic outcomes of different interventions among treatment-experienced patients with 2 consecutive detectable low-level viremia. J Int Assoc Physicians AIDS Care. 2011;10:54-56.
2. Sungkanuparph S, Groger RK, Overton ET, et al. Persistent low-level viraemia and virological failure in HIV-1-infected patients treated with highly active antiretroviral therapy. HIV Med. 2006;7:437-441. (Pubitemid 44269810)
3. Gale HB, Kan VL, Shinol RC. Performance of the TruGene human immunodeficiency virus type 1 genotyping kit and OpenGene DNA sequencing system on clinical samples diluted to approximately 100 copies per milliliter. Clin Vaccine Immunol. 2006;13:235-238. (Pubitemid 43383792)
4. Mitsuya Y, Winters MA, Fessel WJ, et al. HIV-1 drug resistance genotype results in patients with plasma samples with HIV-1 RNA levels less than 75 copies/mL. J Acquir Immune Defic Syndr. 2006;43:56-59. (Pubitemid 44306488)
5. Parkin NT, Deeks SG, Wrin MT, et al. Loss of antiretroviral drug susceptibility at low viral load during early virological failure in treatmentexperienced patients. AIDS. 2000;14:2877-2887. (Pubitemid 32042751)
6. Mackie NE, Phillips AN, Kaye S, et al. Antiretroviral drug resistance in HIV-1-infected patients with low-level viremia. J Infect Dis. 2010;201: 1303-1307.
7. Milia MG, Allice T, Gregori G, et al. Magnetic-silica based nucleic acid extraction for Human Immunodeficiency Virus Type-1 drug-resistance testing in low viremic patients. J Clin Virol. 2010;47:8-12.
8. Stelzl E, Troppan KT, Winkler M, et al. Optimized protocol for detection of HIV-1 drug mutations in patients with low viral load. J Virol Methods. 2010;168:152-154.
9. Verhofstede C, Van Wanzeele F, Van Der Gucht B, et al. Detection of drug resistance mutations as a predictor of subsequent virological failure in patients with HIV-1 viral rebounds of less than 1,000 RNA copies/ml. J Med Virol. 2007;79:1254-1260. (Pubitemid 47106261)
10. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the Drug Resistance Mutations in HIV-1: December 2010. Top HIV Med. 2010;18: 156-163.
11. Parkin NT, Lie YS, Hellmann N, et al. Phenotypic changes in drug susceptibility associated with failure of human immunodeficiency virus type 1 (HIV-1) triple combination therapy. J Infect Dis. 1999;180: 865-870. (Pubitemid 29411380)
12. Aleman S, Soderbarg K, Visco-Comandini U, et al. Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapy. AIDS. 2002;16:1039-1044. (Pubitemid 34499427)
13. Kantor R, Shafer RW, Follansbee S, et al. Evolution of resistance to drugs in HIV-1-infected patients failing antiretroviral therapy. AIDS. 2004;18:1503-1511. (Pubitemid 39037474)
14. Tobin NH, Learn GH, Holte SE, et al. Evidence that low-level viremias during effective highly active antiretroviral therapy result from two processes: expression of archival virus and replication of virus. J Virol. 2005;79:9625-9634. (Pubitemid 41022306)